{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:17:29Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094e7-4ce3-79a0-ac62-565f5d8e7360\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: dopamine antagonist\nSense to describe: (none recorded)\nDomain code: PHY.OBJ\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: ", "usd": 0.0, "recall": true }, "codex": { "seconds": 68.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094e7-4cd8-7e11-9643-20bab3ca1e64\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: dopamine antagonist\nRegistry id: vr.tr.dopamine-antagonist\nPlane / domain: PHY / PHY.OBJ\nRegistry definition: (none recorded)\nNames folded into this " } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:54:00+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q3271533", "registryId": "vr.tr.dopamine-antagonist", "name": "dopamine antagonist", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.OBJ" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q3271533/", "model": { "registry_id": "vr.tr.dopamine-antagonist", "name": "dopamine antagonist", "purpose": "Enable an agent to recognise a dopamine antagonist, assess evidence for its receptor-blocking activity, and identify the conditions and constraints governing its investigation or use.", "definition": "A dopamine antagonist is a substance that binds to one or more dopamine receptor subtypes and inhibits their activation by dopamine.", "scope_statement": "This model owns the pharmacological class registered as vr.tr.dopamine-antagonist in PHY / PHY.OBJ, including criteria for class membership and records linking individual substances to demonstrated dopamine-receptor antagonism.", "in_scope": [ "Dopamine-receptor antagonism as a functional basis for class membership", "Receptor subtype, potency, selectivity and assay-dependent activity", "Relationships between antagonistic activity, active chemical species and exposure", "Evidence supporting experimental or therapeutic roles", "Mechanism-related hazards and substance-specific restrictions" ], "out_of_scope": [ "Complete chemical identity, synthesis and manufacturing specifications for individual compounds", "Dopamine synthesis inhibitors, storage depleters and other indirect mechanisms considered independently", "Dopamine agonists and partial agonists without separately demonstrated antagonistic behaviour", "Finished medicinal products, packaging and supply-chain instances", "Patient diagnosis, prescribing decisions and individual treatment plans" ], "distinguishing_features": [ "Class membership requires evidence of antagonistic activity at a dopamine receptor; merely reducing a dopamine-associated response does not establish direct receptor antagonism.", "Receptor binding alone establishes affinity rather than functional antagonism; a functional result or appropriately qualified pharmacological evidence is needed.", "A partial agonist can oppose dopamine under some conditions while retaining intrinsic activity, so contextual antagonism must be distinguished from classification as a neutral antagonist.", "Dopamine antagonist is a pharmacological class rather than a single chemical substance, formulation or therapeutic indication.", "Antagonism at one dopamine-receptor subtype does not establish equivalent activity across D1, D2, D3, D4 and D5 receptors." ], "characteristics": [ { "name": "Active entity", "kind": "relation", "unit_or_values": "Links to parent compound, active moiety and relevant metabolites", "why_it_matters": "Attributes antagonistic activity to the chemical species actually responsible." }, { "name": "Dopamine-receptor target", "kind": "category", "unit_or_values": "D1, D2, D3, D4, D5; multiple targets; unresolved", "why_it_matters": "Prevents a class label from implying blockade of every dopamine receptor." }, { "name": "Functional activity classification", "kind": "category", "unit_or_values": "Neutral antagonist, inverse agonist, partial agonist with contextual antagonism, mixed or unresolved", "why_it_matters": "Separates blockade of agonist effects from effects on basal receptor activity and intrinsic activation." }, { "name": "Binding affinity", "kind": "measurement", "unit_or_values": "Ki or Kd in nM, with receptor identity and assay conditions", "why_it_matters": "Records binding strength without treating it as proof of functional blockade." }, { "name": "Functional antagonist potency", "kind": "measurement", "unit_or_values": "KB or IC50 in nM, or dimensionless pA2, with method and conditions", "why_it_matters": "Supports comparison only when endpoint, agonist challenge and assay context are compatible." }, { "name": "Antagonism mechanism", "kind": "category", "unit_or_values": "Competitive, noncompetitive, other demonstrated mechanism or unresolved; reversibility recorded separately", "why_it_matters": "Determines how observed blockade depends on agonist concentration and persistence of exposure." }, { "name": "Receptor selectivity", "kind": "measurement", "unit_or_values": "Dimensionless affinity or potency ratios across named targets using comparable assays", "why_it_matters": "Distinguishes dopamine-receptor activity from other pharmacological contributions." }, { "name": "Site-of-action exposure", "kind": "measurement", "unit_or_values": "Unbound concentration in nM and tissue or compartment; unbound brain-to-plasma ratio where available", "why_it_matters": "Connects laboratory activity to whether an active species can reach its receptor." }, { "name": "Dopamine-receptor occupancy", "kind": "measurement", "unit_or_values": "Percent occupancy, with receptor, tissue, method and time after exposure", "why_it_matters": "Records target engagement without equating occupancy with a particular clinical outcome." }, { "name": "Use and evidence status", "kind": "state", "unit_or_values": "Research reagent, investigational use, authorised use or other documented status; jurisdiction and date required", "why_it_matters": "Separates demonstrated pharmacology from permission or evidence for a particular application." } ], "affordances": [ "Assess whether a candidate substance qualifies as a dopamine antagonist under an explicit evidence standard.", "Compare receptor-subtype profiles using compatible binding and functional measurements.", "Trace an observed effect to dopamine-receptor blockade, alternative targets or unresolved mechanisms.", "Identify missing exposure or target-engagement evidence before extrapolating laboratory findings.", "Retrieve substance-specific use restrictions and safety evidence relevant to a proposed activity." ], "agent_conduct": { "may": [ "Explain what dopamine antagonists are and their medical uses from reliable sources.", "Report prescribing information and warnings from regulatory labelling." ], "must_not": [ "Recommend, dose or adjust a dopamine antagonist for a particular person.", "Use these drugs to sedate or control a person without lawful medical authority.", "Downplay side effects such as movement disorders.", "Stigmatize people who take antipsychotic medicines." ], "requires_human": [ "Any prescribing or treatment decision." ] }, "ethics": { "considerations": [ "Some of these drugs have been misused to restrain people, which is a serious violation of dignity.", "People with mental illness deserve accurate, respectful information." ], "affected_parties": [ "Patients", "People in care homes", "Families" ] }, "owners": { "steward": "The prescribing clinician answers for each use; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "failure_modes_and_hazards": [ "Can cause movement disorders, sedation and hormonal effects.", "Inappropriate use in older people with dementia carries serious risks." ], "what_it_is_for": [ "Dopamine antagonists are encountered in pharmacological research and in medicines used for conditions such as psychotic disorders and nausea.", "Their uses depend on receptor selectivity, distribution in the body and the evidence supporting each individual substance." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology classifies medicinal dopamine antagonists according to their therapeutic and pharmacological roles." ], "facets_not_applicable": { "recognition": "Dopamine antagonism is a pharmacological property that cannot be identified reliably from a substance's appearance or dosage form." } }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q3271533: dopamine antagonist", "url": "https://www.wikidata.org/wiki/Q3271533", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Dopamine antagonist", "url": "https://en.wikipedia.org/wiki/Dopamine_antagonist", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "class-identity-and-boundaries", "name": "Class identity and boundaries", "description": "Defines what qualifies as dopamine antagonism and how individual substances relate to the registered class.", "rationale": "A pharmacological class must be recognised through activity rather than a shared chemical structure or indication.", "layers": [ { "id": "membership-criteria", "name": "Membership criteria", "description": "Establishes the evidence needed to apply the class label.", "findings": [ { "id": "direct-receptor-antagonism", "name": "Direct receptor antagonism", "description": "Record whether evidence identifies antagonistic activity at a specified dopamine receptor rather than an indirect reduction of dopamine signalling.", "questions": [ { "text": "What operational definition of dopamine-receptor antagonism determines membership?", "kind": "definition", "id": "direct-receptor-antagonism-q01" }, { "text": "What evidence distinguishes direct receptor antagonism from altered dopamine synthesis, release, storage or clearance?", "kind": "boundary", "id": "direct-receptor-antagonism-q02" } ] } ] }, { "id": "entity-and-role", "name": "Entity and role", "description": "Separates the class, its member substances and the contexts in which those substances act.", "findings": [ { "id": "active-species-attribution", "name": "Active species attribution", "description": "Link the activity claim to the tested chemical species and distinguish it from product names, formulations and precursor substances.", "questions": [ { "text": "Which chemical species was tested, and how is it linked to the named substance or medicinal product?", "kind": "provenance", "id": "active-species-attribution-q01" }, { "text": "Does antagonism belong to the parent compound, an active metabolite or both?", "kind": "boundary", "id": "active-species-attribution-q02" } ] } ] } ] }, { "id": "receptor-pharmacology", "name": "Receptor pharmacology", "description": "Captures dopamine-receptor targets and the functional character of their inhibition.", "rationale": "Subtype and intrinsic activity determine what the label antagonist actually means for a substance.", "layers": [ { "id": "subtype-and-selectivity", "name": "Subtype and selectivity", "description": "Records activity across dopamine-receptor subtypes and relevant alternative targets.", "findings": [ { "id": "target-profile", "name": "Target profile", "description": "Maintain a receptor-specific profile that distinguishes measured inactivity from missing measurements.", "questions": [ { "text": "Which of D1, D2, D3, D4 and D5 have measured binding and functional activity?", "kind": "measurement", "id": "target-profile-q01" }, { "text": "Which comparable measurements establish selectivity over other dopamine subtypes and non-dopamine targets?", "kind": "measurement", "id": "target-profile-q02" } ] } ] }, { "id": "functional-mechanism", "name": "Functional mechanism", "description": "Describes how the substance changes receptor responses under defined conditions.", "findings": [ { "id": "antagonist-behaviour", "name": "Antagonist behaviour", "description": "Distinguish neutral antagonism, inverse agonism and contextual antagonism by a partial agonist, and qualify claims about competition and reversibility.", "questions": [ { "text": "What basal-activity and agonist-challenge measurements support the functional classification?", "kind": "measurement", "id": "antagonist-behaviour-q01" }, { "text": "What experiments establish whether antagonism is competitive, surmountable and reversible?", "kind": "provenance", "id": "antagonist-behaviour-q02" } ] } ] } ] }, { "id": "assay-evidence-and-comparability", "name": "Assay evidence and comparability", "description": "Records how antagonism was measured and what conclusions the measurements support.", "rationale": "Affinity, functional potency and downstream effects answer different questions and cannot be substituted without justification.", "layers": [ { "id": "measurement-context", "name": "Measurement context", "description": "Preserves the experimental details needed to interpret receptor activity.", "findings": [ { "id": "assay-qualified-values", "name": "Assay-qualified values", "description": "Attach each potency or affinity value to its method, biological system, endpoint and experimental conditions.", "questions": [ { "text": "What species, receptor construct or isoform, expression system and signalling endpoint were used?", "kind": "provenance", "id": "assay-qualified-values-q01" }, { "text": "What agonist concentration, incubation time, concentration range and uncertainty accompany the reported value?", "kind": "measurement", "id": "assay-qualified-values-q02" } ] } ] }, { "id": "evidence-strength", "name": "Evidence strength", "description": "Tracks traceability, replication and alternative explanations for apparent blockade.", "findings": [ { "id": "validated-antagonism", "name": "Validated antagonism", "description": "Record source-supported results and controls that distinguish receptor antagonism from assay interference or loss of biological responsiveness.", "questions": [ { "text": "Which inspected primary sources and independent results support the activity claim?", "kind": "provenance", "id": "validated-antagonism-q01" }, { "text": "What controls exclude cytotoxicity, assay interference or inhibition downstream of the dopamine receptor?", "kind": "boundary", "id": "validated-antagonism-q02" } ] } ] } ] }, { "id": "exposure-and-target-engagement", "name": "Exposure and target engagement", "description": "Connects receptor pharmacology to active-species availability at the relevant anatomical site.", "rationale": "Potent antagonism in an assay does not by itself establish blockade in the brain or peripheral tissues.", "layers": [ { "id": "distribution-to-target", "name": "Distribution to target", "description": "Records whether the active species reaches the proposed site of dopamine-receptor blockade.", "findings": [ { "id": "central-and-peripheral-access", "name": "Central and peripheral access", "description": "Distinguish central from peripheral exposure using measured distribution evidence and its limitations.", "questions": [ { "text": "What evidence establishes brain penetration or predominantly peripheral exposure under the studied conditions?", "kind": "measurement", "id": "central-and-peripheral-access-q01" }, { "text": "How do protein binding, transport and active metabolites affect unbound exposure at the proposed receptor site?", "kind": "measurement", "id": "central-and-peripheral-access-q02" } ] } ] }, { "id": "engagement-over-time", "name": "Engagement over time", "description": "Relates exposure duration to measured receptor engagement and functional effects.", "findings": [ { "id": "occupancy-and-persistence", "name": "Occupancy and persistence", "description": "Keep receptor occupancy, functional blockade and effect duration distinct while recording evidence linking them.", "questions": [ { "text": "What receptor occupancy or other target-engagement measurements are available, at which sites and times?", "kind": "measurement", "id": "occupancy-and-persistence-q01" }, { "text": "What evidence links engagement to functional blockade, and how long does blockade persist after exposure declines?", "kind": "boundary", "id": "occupancy-and-persistence-q02" } ] } ] } ] }, { "id": "applications-and-use-constraints", "name": "Applications and use constraints", "description": "Connects dopamine antagonism to supported applications, safety evidence and limits on action.", "rationale": "Shared receptor activity does not establish interchangeable uses, risks or regulatory permissions.", "layers": [ { "id": "supported-applications", "name": "Supported applications", "description": "Separates experimental utility, therapeutic evidence and authorisation for a named substance.", "findings": [ { "id": "use-specific-evidence", "name": "Use-specific evidence", "description": "Record the application and evidence supporting a role for dopamine antagonism without assigning every member the same uses.", "questions": [ { "text": "Which experimental or therapeutic applications are supported for this substance, and what evidence attributes their effects to dopamine-receptor blockade?", "kind": "provenance", "id": "use-specific-evidence-q01" }, { "text": "What current, jurisdiction-specific status and conditions govern the proposed use?", "kind": "action", "id": "use-specific-evidence-q02" } ] } ] }, { "id": "hazards-and-action-limits", "name": "Hazards and action limits", "description": "Records substance-specific hazards and distinguishes receptor-related effects from other mechanisms.", "findings": [ { "id": "mechanism-qualified-risk", "name": "Mechanism-qualified risk", "description": "Assess documented motor, endocrine and other adverse effects with explicit attribution, exposure context and uncertainty.", "questions": [ { "text": "What evidence links observed motor or prolactin-related effects to dopamine-receptor blockade, and which hazards arise from other targets?", "kind": "provenance", "id": "mechanism-qualified-risk-q01" }, { "text": "Which documented contraindications, interactions and monitoring requirements constrain a proposed use of the specific substance?", "kind": "action", "id": "mechanism-qualified-risk-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This entry describes a pharmacological class, not a single chemical substance.", "Receptor selectivity, brain penetration, indications and adverse effects must be checked for each individual agent.", "The description is based on recall; no sources or current regulatory documents were consulted." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "D1-like receptor antagonists, targeting D1 and/or D5 receptors", "D2-like receptor antagonists, targeting D2, D3 and/or D4 receptors", "Antagonists with activity across multiple dopamine receptor subtypes", "Predominantly peripherally acting dopamine antagonists" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Names (INN)", "value_or_pattern": "Individual drug names such as haloperidol, metoclopramide and domperidone", "note": "WHO assigns names to individual drug substances; dopamine antagonist is a pharmacological class, not an individual substance name." }, { "scheme": "CAS Registry Number", "value_or_pattern": "Individual substances have substance-specific registry numbers.", "note": "There is no single CAS number identifying the entire class; salts and other chemical forms may have separate numbers." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Selected agents treat schizophrenia and other psychotic disorders.", "Selected agents treat acute mania.", "Selected agents prevent or treat nausea and vomiting.", "Some agents promote upper gastrointestinal motility.", "Research antagonists help distinguish dopamine receptor functions." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Receptor binding affinity, commonly expressed as Ki", "typical_range": "Compound-, receptor- and assay-dependent; no single class-wide range", "unit": "nM" }, { "quantity": "Dopamine receptor occupancy", "typical_range": "Depends on agent, dose, tissue, receptor subtype and measurement timing", "unit": "%" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Central D2 blockade can cause dystonia, akathisia and drug-induced parkinsonism.", "Prolonged exposure to some agents can cause tardive dyskinesia.", "Some agents elevate prolactin, potentially affecting reproductive and sexual function.", "Neuroleptic malignant syndrome is a rare, potentially life-threatening adverse reaction associated with dopamine-blocking drugs.", "Some agents prolong the QT interval and can cause serious ventricular arrhythmias; risk varies by drug and exposure." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorization, approved indications and prescribing restrictions vary by jurisdiction, notably for domperidone." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Dopamine agonist", "difference": "Activates dopamine receptors rather than blocking their activation." }, { "name": "Dopamine partial agonist", "difference": "Has intrinsic receptor-activating activity, although it can reduce the response to a full agonist under some conditions." }, { "name": "Dopamine synthesis inhibitor", "difference": "Reduces dopamine production rather than directly antagonizing dopamine receptors." }, { "name": "Antipsychotic", "difference": "Defined by therapeutic use; it overlaps with dopamine antagonists but includes other mechanisms, while many dopamine antagonists are used for other purposes." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of dopamine antagonist this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the registry intend this entry to include all dopamine-receptor antagonists or a narrower conventional grouping centred on particular subtypes?", "Should inverse agonists and partial agonists with contextual antagonism be class members or linked neighbouring categories?", "What minimum functional evidence should qualify a substance whose public record reports only receptor binding or an inherited class label?", "Which existing Vercy models already own chemical identity, receptor pharmacology and medicinal-product constraints, and should be linked to avoid duplication?", "Which authoritative sources and comparable primary assays should establish the initial member set and resolve conflicting subtype or potency claims?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }